Trial Profile
A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2 Diabetes Mellitus
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Autologous stem cell therapy (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Cellonis Biotechnologies
- 02 May 2014 Planned initiation date changed from 1 Oct 2010 to 1 Aug 2010.
- 02 May 2014 New trial record